BDBM698591 (R)-1-(6-(4-(5,6-dichloro-1H-indazol-4-yl)-3-(2,2-dimethyl-4-((4-(oxetan-3-yl)piperazin-1-yl)methyl)piperidin-1-yl)-5-methyl-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one::US20240317721, Example 243b

SMILES Cc1c(c(nn1[C@H]1C[C@@]2(C1)CN(C2)C(=O)C=C)N1CC[C@@H](CN2CCN(CC2)C2COC2)CC1(C)C)-c1c(Cl)c(Cl)cc2[nH]ncc12

InChI Key InChIKey=AGXDGCACUVIDKM-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 698591   

TargetGTPase KRas [G12C](Human)
Novartis

US Patent
LigandPNGBDBM698591((R)-1-(6-(4-(5,6-dichloro-1H-indazol-4-yl)-3-(2,2-...)
Affinity DataIC50: 6nMAssay Description:Assays were run using 384-well plates (781207/Greiner) in which one column was designated as the high signal (no inhibition) control, and contained D...More data for this Ligand-Target Pair
In Depth
Date in BDB:
1/28/2025
Entry Details
Go to US Patent